
BIRC7 280-289, QLCPICRAPV
Description
About BIRC7 280-289, QLCPICRAPV
The Human Baculoviral IAP repeat-containing protein (BIRC) 7 Peptide (IEDB: 117066) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Baculoviral IAP repeat-containing protein (BIRC) Peptide, H-QLCPICRAPV-OH (Uniprot: Q96CA5 aa: 280-289) from JPT is produced under strict quality control and quality management.
BIRC7 280-289, QLCPICRAPV - Specifications
- Peptide sequence: H-QLCPICRAPV-OH
- Amount: 10 mg (10 x 1 mg)
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Melanoma
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Request a Quote for you custom antigen peptide!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for BIRC7 280-289, QLCPICRAPV
References:
Read References with JPT’s Antigen Peptides
BIRC7 280-289, QLCPICRAPV has been described in:
Melanoma inhibitor of apoptosis protein (ML-IAP) specific cytotoxic T lymphocytes cross-react with an epitope from the auto-antigen SS56., J Invest Dermatol, 2009 (PMID: 19212346)
Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade., Front Immunol, 2022 (PMID: 35874702)
Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer., Cancer Res, 2000 (PMID: 11034097)
Documentation
Documentation for BIRC7 280-289, QLCPICRAPV
Properties
Properties of BIRC7 280-289, QLCPICRAPV
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Melanoma |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Protein Name: | Baculoviral IAP repeat-containing protein (BIRC) |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to BIRC7 280-289, QLCPICRAPV
Information | Values |
---|---|
Sequence: | H-QLCPICRAPV-OH |
Specifications: | 10mer peptide as TFA salt |